May 2023: |
|
Assessing the potential of new travel vaccines |
|
March 2022: |
|
A third of the major vaccine company pipeline is mRNA |
|
November 2021: |
|
Epstein-barr virus vaccines - preventing downstream risk |
|
November 2020: |
|
Seasonal influenza vaccines and the mRNA threat |
|
August 2020: |
|
The vaccine industry - filling the $2.5bn hole |
|
June 2020: |
|
Norovirus vaccines - rethinking market segments |
|
June 2019: |
|
A new Lyme disease vaccine - bravery to be rewarded |
|
August 2018: |
|
Pfizer's BioNTech influenza deal - the bold latecomer |
|
July 2018: |
|
A Lassa Fever vaccine - follow the footsteps of Ebola |
|
February 2018: |
|
FY 2017 vaccines sales data - major players [premium] |
|
January 2018: |
|
An opioid use disorder vaccine |
|
November 2017: |
|
3Q vaccines sales data - major players |
|
August 2017: |
|
H1 (2Q) vaccines sales data - major players |
|
May 2017: |
|
Conference Report: 3rd ICVI London |
|
April 2017: |
|
2016 FY results - the impact of real use and true product innovation. |
|
February 2017: |
|
Vaccines in the Trump era. |
|
December 2016: |
|
2016 - year of the flavivirus vaccine. |
|
November 2016: |
|
2017 places higher pressure on hospitals to avoid HAIs. |
|
September 2016: |
|
A Zika vaccine - the case strengthens. |
|
May 2016: |
|
The global influenza vaccine market - where next? |
|
March 2016: |
|
2015 FY - Pfizer grows vaccine industry. |
|
February 2016: |
|
A Zika vaccine - late to the party we must attend |
|
December 2015: |
|
2015 - The year of meningitis vaccines |
|
August 2015: |
|
2015 Q2 - round up of results and R&D |
|
May 2015: |
|
Human metapneumovirus - why the poor cousin of RSV? |
|
March 2015: |
|
2014 FY Results - vaccine industry, still bumping along. |
|
December 2014: |
|
Top ten vaccine industry events - 2015. |
|
November 2014: |
|
Influenza vaccines - more options but don't lose sight of longer term. |
|
October 2014: |
|
No room for blame after our surprise from Ebola. |
|
September 2014: |
|
54th ICAAC, Washington DC conference - selective innovation won't do. |
|
August 2014: |
|
Pfizer vaccines boosts presence with low risk Baxter acquisitions. |
|
June 2014: |
|
Caribbean Chikungunya outbreak should move vaccine back onto the agenda. |
|
April 2014: |
|
Novartis to the vaccines industry - can we have our money back please? |
|
March 2014: |
|
Bexsero�: good for UK children, Novartis Vaccines and a flat industry. |
|
February 2014: |
|
2013 FY results - QIVs a highlight in a flat industry |
|
|
December 2013: |
|
Clostridium difficile vaccines: multipronged US-biased strategy to reduce economic burden. |
|
|
November 2013: |
|
Meningococcal group B vaccine, Bexsero�: too late for the science? Stick to the wider economics |
|
|
October 2013: |
|
Who will benefit from the predicted boom in inactivated polio virus vaccines? |
|
|
September 2013: |
|
Middle East respiratory syndrome coronavirus (MERS-CoV) - worry, but dont panic. |
|
|
August 2013: |
|
Q2 2013 - Roundup of results and R&D |
|
|
June 2013: |
|
M&A in the vaccine sector. |
|
|
March 2013: |
|
PCSK9 mAbs or even vaccines - the new statins? |
|
|
February 2013: |
|
2012 FY results - a flat industry poised for growth. |
|
|
January 2013: |
|
Protein Sciences FluBlok - finally here but much still to be done. |
|
|
December 2012: |
|
2012 - another year for the vaccine industry. |
|
|
October 2012: |
|
Latest review of the vaccine R&D pipeline - Autumn 2012. |
|
|
August 2012: |
|
The vaccines industry: Q2 2012 round-up of results and R&D. |
|
|
June 2012: |
|
Quadrivalent influenza vaccines: full switch or niche position? |
|
|
April 2012: |
|
Is it still worth developing a Staph vaccine? |
|
|
February 2012: |
|
2011 FY Results - vaccine industry waiting for next burst of growth. |
|
|
January 2012: |
|
A(H5N1), Avian influenza - still with us, ready to pounce? |
|
|
November 2011: |
|
Vaccine major players - Q3 round-up of results and R&D. |
|
|
September 2011: |
|
XVIII Lancefield International Symposium, Palermo, Sicily......vaccine update. |
|
|
June 2011: |
|
Melanoma vaccines - have Roche and BMS moved the goal posts? |
|
|
May 2011: |
|
New vaccines for dengue. Paying adults please. |
|
|
March 2011: |
|
2010 FY Results. Its more than H1N1....... |
|
|
January 2011: |
|
The current industry landscape for therapeutic vaccines. |
|
|
December 2010: |
|
The vaccine industry in 2010 - highlights and lowlights. |
|
|
November 2010: |
|
How much is the current R&D vaccine pipeline worth? |
PREMIUM |
Vaccine major players - Q3 round up of results and R&D |
|
|
September 2010: |
|
Discussing vaccines at the 50th ICAAC Boston. |
|
|
August 2010: |
|
Vaccine major players - Q2 round up of results and R&D |
|
Considerations when commercial modelling a universal influenza vaccine. |
PREMIUM |
|
June 2010: |
|
A credible GBS vaccine - finally back on the agenda |
|
|
May 2010: |
|
Vaccine major players - Q1 round up of results and R&D |
|
|
April 2010: |
|
Healthcare acquired infections and vaccines - the profile determines everything. |
PREMIUM |
|
March 2010: |
|
Vaccines and Japanese Encephalitis - too early to call for Ixiaro? |
|
|
February 2010: |
|
The vaccine industry in 2009 - well past the $20 billion barrier. |
|
|
January 2010: |
|
H1N1 - boost to Novartis Vaccines, the industry but for how long? |
|
|
December 2009: |
|
2009 and vaccines - lots of activity, and surprises. |
|
|
November 2009: |
|
New meningitis B vaccines - does the best science matter? |
PREMIUM |
Rethinking new meningitis ACWY vaccines. |
|
How to monitor fast moving vaccine R&D. |
|
|
October 2009: |
|
New vaccine adjuvants - MPL paves the way. |
|
H1N1 vaccines - the pros and cons of new technologies. |
|
|
September 2009: |
|
Vaccinating teenagers - growth platform. |
|
|
August 2009: |
|
Enterovirus-71: a long-term bet for the SE Asia region? |
PREMIUM |
Latest vaccine R&D pipeline - flu sets agenda. |
|
|
June 2009: |
|
Chikungunya virus - should we think now about a vaccine? |
|
Prevnar and PCV-13 versus Synflorix - waging war at 27th ESPID with antibody levels. |
PREMIUM |
|
May 2009: |
|
Major vaccine players - the race to Japan. |
|
Modelling H1N1 vaccine demand - another multibillion dollar issue. |
|
|
April 2009: |
|
Swine flu (H1N1) reminds us our flu vaccine technologies need updating. |
|
GSKs Synflorix and Non-typeable H.influenzae - the secret to beating Wyeth? |
PREMIUM |
|
March 2009: |
|
Pandemic flu - building the case to prime now. |
|
|
February 2009: |
|
The vaccine industry - still growing, but more slowly. |
|
|
January 2009: |
|
GSK and Synflorix: closer to a different marketplace? |
PREMIUM |
Wyeth and vaccines: first acquiring then acquired. |
|
US Pandemic Planning Update VI - strong vaccine progress to date. |
|